Autism Impact Fund

What Autism Impact Fund does

Autism Impact Fund (AIF) is a US-based venture capital firm founded in 2020/2021 by Christopher Male, Brian O'Callaghan, and Elizabeth Horn, focused exclusively on investments in autism, behavioral health, mental health, and complex chronic conditions. The firm deploys capital across two thematic pillars: life sciences (diagnostics, gene therapy, gut-targeted small molecule drugs, and ASD therapeutics) and data/tech-enabled services (telehealth, ABA electronic health records, virtual reality therapy, AI caregiving, neurodiverse employment, and value-based pediatric care). Fund I closed at $60M in April 2024 across 14 portfolio companies, and Fund II closed at $150M with an explicit emphasis on AI-enabled solutions and value-based care models.

AIF operates an ecosystem-driven investment model anchored by a Scientific Advisory Board (including former NIH Director Dr. Tom Insel, UC Davis's Dr. David Amaral, and Harvard/MGH's Dr. Jacob Hooker) and an Investment Advisory Board drawing senior executives from Uber, ARCH Venture Partners, Samsung, Microsoft, and Ferd. The firm sources deals through deep relationships with the 2m Foundation's COMPASS network, Vanderbilt's Frist Center for Autism and Innovation, Jonathan's Landing Foundation, and the non-profit platform Multiple. Co-founder Christopher Male sourced nearly all Fund I investments directly.

The business model follows standard venture economics: management fees on committed capital plus carried interest on exits. Reported portfolio outcomes include an 83% reduction in ASD diagnosis wait times (via Healios/Meliora Health), 800,000+ individuals reached through point-of-care expansion, 49 clinical trials advanced, and two exits (Joshin and SpectrumAi). AIF maintains offices in New York, San Francisco, Winter Park, and Nashville, with a lean operating team of approximately 9 core staff supplemented by the advisory boards.

Name

Autism Impact Fund

Legal name

Autism Impact Fund

Website

https://autismimpact.fund

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Autism Impact Fund is a US venture capital firm founded in 2020/2021 that invests exclusively in autism, behavioral health, mental health, and complex chronic conditions, deploying Fund I ($60M) and Fund II ($150M) across life sciences and data/tech-enabled services portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital / Impact Investing

NAICS

Open-End Investment Funds (52591)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital investing
• Autism healthcare investments
• Life sciences portfolio
• Behavioral health funding
• Impact investment fund

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Management Fees: AIF generates revenue through standard venture capital management fees on deployed capital from Fund I ($60M) and Fund II ($150M). These fees typically cover operational costs and are calculated as a percentage of committed capital under management.
2. Carried Interest (Carry): As a venture capital fund, AIF earns carried interest on successful exits and realizations from portfolio companies. Fund II is focused on AI-enabled solutions and value-based care models with emphasis on investments that improve outcomes and reduce costs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Autism Impact Fund is a venture capital and growth capital firm that invests in early-to-growth stage healthcare companies developing diagnostics, digital health solutions, therapeutics, and care delivery models for autism, behavioral health, mental health, and complex chronic conditions. The firm deploys capital from Fund I ($60M) and Fund II ($150M) across 14+ portfolio companies, providing not just capital but operational support, scientific guidance, and ecosystem connections to help portfolio companies scale and commercialize innovations.

Product overview

Autism Impact Fund (AIF) is a healthcare technology and innovation venture capital firm that does not offer a single unified product but rather maintains a diversified portfolio ecosystem of early- and growth-stage companies advancing diagnostics, digital health, therapeutics, and care delivery for autism, behavioral health, mental health, and complex chronic conditions. The portfolio is organized into Life Sciences companies (BioROSA for ASD blood testing, Yamo Pharmaceuticals for L1-79 therapeutics, MARAbio for maternal autoantibody testing, Jaguar Gene Therapy for gene therapy, Vertero/Axial Therapeutics for gut-targeted neurological treatments) and Data & Tech-Enabled Services companies (Auticon for neurodiverse IT consulting, Floreo for VR-based therapy, Cortica for integrated pediatric care, Healios/Meliora Health for telehealth, Camber for behavioral health SaaS, Suggestic for AI-powered wellness coaching, SpectrumAi for ABA EHR and analytics, Bluebird Kids Health for value-based pediatric care, Imagine Pediatrics for virtual/in-home pediatric services, Joshin for caregiver matching, Eleplan for AI-powered care coordination, Unison Therapy Services for multidisciplinary therapy). The fund's ecosystem-driven approach cultivates collaboration across portfolio companies, corporate partners, nonprofits, academic institutions, and families to drive innovation from early childhood through adulthood.

Differentiator

Problem solved

Functional benefit

Products and services

• Autism Impact Fund - Fund I Venture capital fund deploying $60 million across early-to-growth stage companies developing diagnostics, digital health, therapeutics, and care delivery solutions for autism, behavioral health, mental health, and complex chronic conditions. Fully deployed across 14 portfolio companies.
• Autism Impact Fund - Fund II Venture capital fund deploying $150 million focused on AI-enabled solutions and value-based care models for autism, behavioral health, mental health, and complex chronic conditions.

Quantifiable outcome

• 83% reduction in wait times for ASD diagnosis
• +3 more outcomes

Named customers17 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Eleven partnerships are on record, tiered core and strategic.

• MultiplecoreStrategic or Co-development Partner · 15 November 2022Strategic partnership with Multiple, a non-profit innovation platform for the autism community. The partnership harnesses unique capabilities of each organization to bring new solutions to the market that benefit individuals and families impacted by Autism Spectrum Disorder.
• 2m Foundation / COMPASS NetworkcoreStrategic or Co-development PartnerFounding partner network from which AIF emerged. The 2m Foundation's COMPASS network connects parents, investors, and scientists who share a common belief that private industry and venture capital could accelerate the pace of innovation for autism and related conditions.
• Frist Center for Autism and Innovation at Vanderbilt UniversitycoreStrategic or Co-development PartnerStrategic partnership with the Frist Center, a major autism research and innovation center at Vanderbilt University. Co-Founder Chris Male serves as a board member. The partnership provides access to research expertise and helps advance the autism innovation ecosystem.
• Jonathan's Landing FoundationcoreStrategic or Co-development PartnerPartnership with Jonathan's Landing Foundation, founded by AIF advisor Jason Eichenholz. The foundation supports autism innovation and research, providing AIF with additional ecosystem connections and resources.
• UC Davis MIND InstitutecoreStrategic or Co-development PartnerPortfolio company MARAbio has exclusively licensed technology from the UC Davis MIND Institute for Maternal Autoantibody Related Autism (MARA) testing. Dr. David Amaral, Director of the Autism Center of Excellence at UC Davis, serves on AIF's Scientific Advisory Board.
• Arkansas Children's HospitalstrategicStrategic or Co-development PartnerDr. Richard Frye, Director of Autism Research at Arkansas Children's Hospital, serves on AIF's Scientific Advisory Board, providing expertise in autism research and potential investment evaluation.
• Massachusetts General Hospital / Lurie Center for AutismstrategicStrategic or Co-development PartnerDr. Jacob Hooker, Scientific Director of the Lurie Center for Autism at Massachusetts General Hospital and Professor of Radiology at Harvard Medical School, serves on AIF's Scientific Advisory Board.
• Autism Science FoundationstrategicStrategic or Co-development PartnerAlison Singer, Co-Founder and President of the Autism Science Foundation, serves on AIF's Scientific Advisory Board, connecting AIF to the autism research and advocacy community.
• UberstrategicStrategic or Co-development PartnerDara Khosrowshahi, CEO of Uber, serves on AIF's Investment Advisory Board. Uber's CEO serves as an advisor to the fund, providing strategic guidance and industry connections.
• SamsungstrategicStrategic or Co-development PartnerCuong Do, President of Samsung Corporate Strategy Group, serves on AIF's Investment Advisory Board, providing corporate strategy and global business expertise.
• MicrosoftstrategicStrategic or Co-development PartnerMike Edmonds, Senior Director at Microsoft, serves on AIF's Investment Advisory Board, contributing technology and enterprise expertise.

Scale indicators11 records

Recent moves6 records

Broad incumbents

• Omega Funds:
• ARCH Venture Partners: One of the largest early-stage biotech and life sciences venture firms, co-founded by Bob Nelsen who also sits on AIF's Investment Advisory Board. Highly comparable given shared focus on life sciences and biotech venture investing at the earliest stages, though ARCH operates across all therapeutic areas at significantly larger fund sizes.
• Bain Capital Life Sciences: Dedicated life sciences platform within Bain Capital deploying venture and growth capital into biotech, pharma services, and medical devices. Comparable to AIF's life sciences practice in stage approach and clinical-asset focus, though at materially larger fund sizes and across all therapeutic areas.

Direct peers

• Frazier Healthcare Partners: Healthcare-dedicated venture and growth capital firm investing across biopharma and healthcare services. Comparable to AIF in sector specialization, stage diversity (seed through growth), and focus on commercializing innovative healthcare companies, though broader in therapeutic scope and significantly larger AUM.
• Vivo Capital: Healthcare-focused investment firm operating venture, growth, and public equity strategies across life sciences and healthcare services. Comparable to AIF in sector specialization and stage diversity, with a similar emphasis on commercializing differentiated healthcare innovations in US and Asia.
• Longitude Capital: Healthcare-focused venture and growth equity firm investing in drug development, medical devices, and healthcare services. Closely comparable to AIF in mandate scope (life sciences plus tech-enabled services), stage approach (early through growth), and impact-oriented healthcare investing thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/autismimpactfund

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autism Impact Fund